Specialty Pharma Journal Specialty, Precision & Technology
LONDON and WALTHAM, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) — GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) today announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion). The proposed transaction …
Tag Archives: M&As
December, 2018
November, 2018
-
29 November
CVS Health Completes Acquisition of Aetna, Marking the Start of Transforming the Consumer Health Experience
Woonsocket, RI (November 28, 2018) – CVS Health (NYSE: CVS), a company that is leading the transformation of health care, today announced that it has completed its acquisition of Aetna (NYSE: AET), establishing CVS Health as the nation’s premier health innovation company. “Today marks the start of a new day in …
-
28 November
Genentech Gains Rights to Portfolio of NLRP3 Inhibitors through Acquisition of Jecure Therapeutics
SAN DIEGO–(BUSINESS WIRE)–Jecure Therapeutics Inc., a biotechnology company with novel drug discovery programs targeting serious inflammatory diseases, today announced a definitive agreement by which it will be acquired by Genentech, a member of the Roche Group. With this acquisition, Genentech will obtain full rights to Jecure’s entire preclinical portfolio of …
-
20 November
Boston Scientific Offers to Buy UK Medical Device Firm BTG for $4.2 Billion
MARLBOROUGH, Mass., Nov. 20, 2018 /PRNewswire/ — Boston Scientific (NYSE: BSX) today announced it has reached an agreement on the terms of a recommended offer to acquire BTG plc. (LSE: BTG), a company headquartered in the United Kingdom, which develops and commercializes products used in minimally-invasive procedures targeting cancer and vascular diseases, as well …
-
2 November
Illumina to Acquire Pacific Biosciences for Approximately $1.2 Billion, Broadening Access to Long-Read Sequencing and Accelerating Scientific Discovery
SAN DIEGO & MENLO PARK, Calif.–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) and Pacific Biosciences (NASDAQ:PACB) today announced they have signed an agreement for Illumina to acquire Pacific Biosciences at a price of $8.00 per Pacific Biosciences share in an all-cash transaction. This price represents a premium of 71% to Pacific Biosciences’ …
October, 2018
-
19 October
Novartis to Pay $2.1 Billion for Acquisition of Cancer Drugmaker Endocyte
Basel, October 18, 2018 – Novartis today announced that it has entered into an agreement and plan of merger with Endocyte, a US-based biopharmaceutical company focused on developing targeted therapeutics for cancer treatment. Under the terms of the agreement, Novartis would acquire all outstanding shares of Endocyte common stock for USD 24 …
-
5 October
Teleflex Acquires Essential Medical
WAYNE, Pa.–(BUSINESS WIRE)–Teleflex Incorporated (NYSE: TFX) today announced that it has acquired Essential Medical, Inc. Based in Exton, PA, Essential Medical is a privately-held medical device company that has developed and commercialized the CE Marked MANTA™ Vascular Closure Device specifically designed for closure of large bore arteriotomies following procedures utilizing …
September, 2018
-
27 September
Quest Diagnostics Acquires PhenoPath, Broadening Access to Advanced Diagnostics
SECAUCUS, N.J. and SEATTLE, Sept. 27, 2018 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that it has acquired PhenoPath, a national provider of specialized anatomic pathology (AP) and related services. Based in Seattle, PhenoPath provides AP, molecular oncology and other services that complement and extend those of …
-
27 September
Hologic to Acquire Focal Therapeutics for $125 Million, Strengthening Breast Surgery Franchise
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that it has signed a definitive agreement to acquire Focal Therapeutics, a privately-held company, for $125 million in cash. In conjunction with Hologic’s recent acquisition of Faxitron Bioptics, Focal strengthens the Company’s position in the rapidly …
-
27 September
Agilent to Expand Portfolio and Capabilities in Cell Analysis with Acquisition of ACEA Biosciences
SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A) today announced it has signed a definitive agreement to acquire privately-owned ACEA Biosciences Inc. (ACEA), a developer of cutting-edge cell analysis instruments for life science research and clinical diagnostics, for $250 million in cash. “Expanding our cell analysis footprint is a key strategic …